Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C1832526 (
PCC
)
5,967
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Lactase-phlorizin hydrolase
(
LPH
) synthesis is restricted to differentiated small intestinal enterocytes and is highly regulated during development. Analysis of expression of
LPH
promoter segments fused with luciferase transfected in Caco-2 cells, a line that uniquely expresses
LPH
mRNA, mapped an 18-base pair (bp) segment 100 bp upstream of the transcription start site that is required for transactivation. Remarkably, the
LPH
upstream element (LUE) has no stimulatory activity in both human intestinal and nonintestinal lines in which
LPH
mRNA is absent. Electrophoretic analysis of sequence-specific DNA-nuclear protein complexes demonstrated the presence of a Caco-2 cell-specific protein(s) (
CCP
), which is uniformly absent in
LPH
nonproducer cell lines. Mutational analysis of the LUE demonstrated that bases contained within a GATA consensus motif are critical for both
CCP
binding and transcription from the
LPH
promoter. Caco-2 cells express high levels of GATA-6 mRNA in a cell line-specific manner, suggesting that GATA-6 is a
CCP
that complexes with the LUE. When expressed by a plasmid, GATA-6 transactivated the
LPH
promoter. The stimulation was abrogated with mutations in the GATA consensus motif as well as mutations in a flanking downstream element. These studies are consistent with an important role of an intestinal GATA binding protein in cell type-specific transactivation of the
LPH
promoter.
...
PMID:GATA-6 stimulates a cell line-specific activation element in the human lactase promoter. 948 85